Cue Biopharma
CUE
89 hedge funds and large institutions have $229M invested in Cue Biopharma in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 31 increasing their positions, 33 reducing their positions, and 14 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.07% less ownership
Funds ownership: 2.13% → 2.06% (-0.07%)
5% less capital invested
Capital invested by funds: $241M → $229M (-$12M)
6% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 33
8% less funds holding
Funds holding: 97 → 89 (-8)
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
76% less call options, than puts
Call options by funds: $732K | Put options by funds: $3.06M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$8.69M |
| 2 |
AR
Advisory Research
Chicago,
Illinois
|
+$3.51M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.71M |
| 4 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$2.18M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$5.66M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$4.8M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$4.22M |
| 4 |
Millennium Management
New York
|
-$3.9M |
| 5 |
Morgan Stanley
New York
|
-$3.09M |
CUE Hedge Fund Activity: Q1 2021 in Review
89 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q1 2021, worth a combined $229M — down 5% from $241M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CUE and 6 opened new positions — a net loss of 8 holders — while 33 trimmed existing stakes and 31 added.
The largest buyer was Corriente Advisors, adding an estimated $8.69M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $5.66M sold.
- 89 institutional investors held Cue Biopharma (CUE) as of Q1 2021, down from 97 in Q4 2020.
- Funds reported $229M of Cue Biopharma stock for Q1 2021, down 5% quarter-over-quarter.
- 6 funds opened new Cue Biopharma positions in Q1 2021 and 14 closed out, a net change of -8 holders.
- The largest Cue Biopharma buyer in Q1 2021 was Corriente Advisors, an estimated $8.69M added.
- The largest Cue Biopharma seller in Q1 2021 was Avoro Capital Advisors, an estimated $5.66M sold.
Based on aggregated 13F filings for Q1 2021.